Our findings open the door to exploring how small-molecule inhibitors or modulators of the RSK2:ERK2 interaction might be designed to disrupt or modulate the signaling pathways in which these kinases are involved, with implications for cancer, neurobiology, and other diseases. This evidence concerns the gene RPS6KA3 and cancer.